GLAM
JAZZ icon

Gardner Lewis Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gardner Lewis Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,300
Closed -$2.54M – 106
2017
Q2 		$2.54M Buy
+16,300
New +$2.49M 0.17% 66

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Gardner Lewis Asset Management's JAZZ Position: Q3 2017 in Review

Gardner Lewis Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 16,300 shares — an estimated $2.54M sold.

Gardner Lewis Asset Management first reported a position in JAZZ in Q2 2017 and held it in 1 quarter. The position peaked at $2.54M in Q2 2017. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Gardner Lewis Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Gardner Lewis Asset Management sold 16,300 Jazz Pharmaceuticals shares in Q3 2017, an estimated $2.54M.
  • Gardner Lewis Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Gardner Lewis Asset Management's Jazz Pharmaceuticals position peaked at $2.54M in Q2 2017.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Gardner Lewis Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.